Compare Danaher Corporation (DHR) vs Strategy Inc. (MSTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Strategy Inc. — how do they compare? Danaher Corporation trades at $217 (market cap $153.60B), while Strategy Inc. trades at $154.98 (market cap $61.16B). The key difference: Danaher Corporation is far larger — about 2.5× Strategy Inc.'s market cap, and Danaher Corporation pays a 0.73% dividend while Strategy Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Strategy Inc. for 112 Days on average.
| DHR | MSTR | |
|---|---|---|
Market Cap | $153.60B | $61.16B |
Volume | 3,974,063 | 21,318,561 |
Sector | Health | Technology |
52-Week High | $242.05 | $320.29 |
52-Week Low | $161.91 | $82.31 |
Typical Hold Time | 69 Days | 112 Days |
Enterprise Value | $175.81B | $79.92B |
Dividend Yield | 0.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, up 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $24.57B in 2025, though net margins have compressed from historical highs. A quarterly dividend of $0.40 was declared, payable in October 2026.
The outlook remains positive given earnings momentum and institutional accumulation, but valuation multiples are elevated. Risks include margin pressure and high capital expenditure in 2026. The consensus price target of $230.31 implies modest upside, supported by 70% buy ratings from analysts.
MSTR stock trades at $151.47, down 7.95% over 24 hours, with a bullish technical signal from moving averages. The company reported a net loss of $3.85 billion for 2025 on revenue of $477.23 million, with a deeply negative net income margin of -6,102.96%. Despite severe profitability challenges, analyst consensus remains optimistic with a $252 price target, and recent news highlights significant stock volatility tied to Bitcoin market movements.
The outlook is bifurcated: strong analyst buy ratings and a high price target suggest upside potential, but fundamental weaknesses including persistent losses and negative cash flow from operations pose substantial risks. Investment appeal hinges on speculative sentiment rather than current financial health, with volatility expected to continue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →
